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Abstract
Background: The physiological effects of prostaglandin E1 (PGE1) and prostaglandin E2 (PGE2) are mediated by the 
prostaglandin E receptor subtypes EP1, EP2, EP3, and EP4, and the respective agonists have been purified. PGE1 and 
PGE2 can increase the production of vascular endothelial growth factor (VEGF), particularly through EP2 and EP4. The 
biological effects of VEGF are mediated by the phosphotyrosine kinase receptors fms-related tyrosine kinase-1 (Flt-1) 
and fetal liver kinase-1 (Flk-1). Here we examined the effects of EP2 and EP4 agonists on the production of VEGF 
proteins and VEGF messenger RNAs (mRNAs) in the inner ear, using an enzyme-linked immunosorbent assay and the 
real-time quantitative reverse transcription-polymerase chain reaction, respectively. We also examined the localization 
of EP2, VEGF, Flt-1, and Flk-1 in the cochlea by immunohistochemistry.
Results: The expression of EP2 occurred in the cochlea, and the local application of an EP2 or EP4 agonist increased 
VEGF protein and VEGF mRNA levels in the inner ear. Furthermore, the intensity of the VEGF immunoreactivity in the 
spiral ganglion appeared to be increased by the local EP2 or EP4 agonist treatment. Immunoreactivity for Flt-1, and Flk-
1 was found in the cochlear sensory epithelium, spiral ganglion, spiral ligament, and stria vascularis.
Conclusions: These findings demonstrate that EP2 and EP4 agonists stimulate VEGF production in the inner ear, 
particularly in the spiral ganglions. Moreover, the Flt-1 and Flk-1 expression observed in the present study suggests that 
VEGF has autocrine and paracrine actions in the cochlea. Thus, EP2 and EP4 might be involved in the mechanisms 
underlying the therapeutic effects of PGE1 on acute sensorineural hearing loss via VEGF production.
Background
Sensorineural hearing loss (SNHL) is a common disabil-
ity. Once hearing has been lost, it is rarely recovered. The
systemic application of corticosteroids has been accepted
as the treatment of choice for acute SNHL, although its
efficacy has not been substantiated [1]. In general,
approximately 50% of SNHL cases show no response to
the systemic application of corticosteroids [2]. Hence
there is an urgent need to develop alternative treatments
for acute SNHL. Prostaglandin E1 (PGE1) has often been
used as one such treatment; however, its clinical efficacy
remains controversial [3-5]. The physiological actions of
PGE1 and prostaglandin E2 (PGE2) are mediated by the
prostaglandin E receptor subtypes EP1, EP2, EP3, and
EP4 [6,7]. EP2 and EP4 are coupled to G-protein stimula-
tion, and mediate increases in cyclic adenosine mono-
phosphate (cAMP) that activate protein kinase A (PKA)
[7,8]. By contrast, the activation of EP3 decreases cAMP
levels, which suggests that the selective activation of EP2
and/or EP4 might increase the clinical efficacy of PGE1
for the treatment of acute SNHL. Based on these find-
ings, we previously examined the expression of EP4 in the
cochlea, and the potential of an EP4 agonist to protect the
cochlea against noise-induced trauma [9]. Our results
demonstrated both EP4 e xpression in the cochlea, and
cochlear protection against noise trauma as a result of the
local application of an EP4 agonist. However, the exact
mechanisms by which EP4 agonists act in the cochlea are
presently unclear and require further research.
Among their various physiological and pathophysiolog-
ical functions, PGE1 and PGE2 are known to increase
vascular endothelial growth factor (VEGF) production
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via a cAMP-dependent mechanism, which is mediated by
EP2 and EP4 [10-13]. VEGF, which is a 45-kDa heparin-
binding homodimeric glycoprotein, plays roles in angio-
genesis, vasodilation, differentiation, anti-apoptosis, pro-
liferation, and vascular permeability in endothelial tissues
[14-16]. It also has neurotrophic and neuroprotective
effects in non-endothelial tissues [17-19]. Recent studies
h a v e  i n d i c a t e d  t h a t  V E G F  a l s o  p r o t e c t s  t h e  c o c h l e a
against noise trauma [20,21]. Based on these findings, we
hypothesized that VEGF is involved in the mechanisms
underlying the cochlear protection against noise trauma
that results from local EP4 agonist application. We thus
examined the expression of EP2 in the cochlea, and the
effects of local EP2 and EP4 agonist application on the
modulation of VEGF in the inner ear. The current study
demonstrated an increase in the levels of VEGF proteins
and messenger RNAs (mRNAs) following local EP2 and
EP4 agonist application according to an enzyme-linked
immunosorbent assay (ELISA), immunohistochemistry,
and the real-time quantitative reverse transcription-poly-
merase chain reaction (qRT-PCR). We also demonstrated
the expression of VEGF receptor-1 (VEGFR-1) or fms-
related tyrosine kinase-1 (Flt-1), and VEGF receptor-2
(VEGFR-2) or fetal liver kinase-1 (Flk-1), which mediate
the physiological actions of VEGF in the cochlea [22,23].
Results
EP2 expression in cochleae
Our previous study demonstrated the localization of EP4
in the mouse cochlea [9]; however, EP2 expression in the
mouse cochlea has not been determined. We thus per-
formed an immunohistochemical analysis of EP2 using
normal mouse cochlear specimens in the current study.
Immunostaining revealed that the EP2 expression
occurred in the stria vascularis, spiral ligament, spiral
ganglion neurons, supporting cells, and hair cells (Figure
1). Negative controls using a specific blocking peptide
showed no immunoreactivity (data not shown). These
findings confirmed that EP2 expression was present in
the cochlear cells, similar to EP4 [9].
VEGF increase due to EP2 and EP4 agonists
To examine the changes in the expression of VEGF pro-
teins and VEGF mRNAs in the inner ear caused by EP2
and EP4 agonists, we performed ELISA and real-time
qRT-PCR analyses of extracts from inner ear specimens
following the local application of EP2 and EP4 agonists or
control substrates. ELISA analyses revealed significant
increases in VEGF protein levels following EP2 agonist
application at concentrations of 0.01 and 0.1 mg/ml (Fig-
ure 2A; p < 0.001 and p = 0.005, respectively). No signifi-
cant increase of VEGF protein levels was found in
samples treated with 1 mg/ml EP2 agonist. The maxi-
mum VEGF protein increase was found at a concentra-
tion of 0.1 mg/ml. Local application of an EP4 agonist
also caused a significant increase of VEGF protein levels
in the inner ear. Specimens treated with 0.01 or 0.1 mg/
ml EP4 exhibited significantly higher VEGF protein levels
than those treated with 0.01 or 0.1% dimethyl sulfoxide
(DMSO) (Figure 2B; p = 0.004 and 0.026, respectively).
No significant increase of VEGF protein levels was identi-
fied in samples treated with 1 mg/ml EP4 agonist in com-
parison with those treated with 1% DMSO. The EP4
agonist caused a maximum VEGF protein increase at a
concentration of 0.01 mg/ml.
Real-time qRT-PCR analyses demonstrated a signifi-
cant increase of VEGF mRNA levels following the local
application of the EP2 and EP4 agonists. The relative
VEGF expression levels in the samples treated with 0.01
or 0.1 mg/ml EP2 agonist were significantly higher (p <
0.001 and p = 0.007, respectively) than those in the con-
trol samples treated with saline (Figure 3A). There was no
significant difference in the relative VEGF expression lev-
els between the samples treated with 1 mg/ml EP2 ago-
nist and the control samples, similar to the VEGF protein
levels. The relative VEGF expression levels in the samples
treated with 0.01 and 0.1 mg/ml EP4 agonist were signifi-
cantly higher (p  = 0.002 and 0.036, respectively) than
those in the control samples treated with DMSO (Figure
3B). The samples treated with 1 mg/ml EP4 agonist
exhibited no significant increase of VEGF mRNA levels in
comparison with the control samples treated with
DMSO, similar to the VEGF protein levels. The maxi-
mum increases in VEGF  mRNA levels were observed
after treatment with 0.1 mg/ml EP2 and 0.01 mg/ml EP4,
similar to the VEGF protein levels. These results demon-
strated that the EP2 and EP4 agonists stimulated VEGF
production in the inner ear.
VEGF expression in cochleae
Our previous study [9] and immunostaining for EP2 in
the present study demonstrated the presence of EP2 and
EP4 in various types of cochlear cells. ELISA and real-
time qRT-PCR analyses revealed VEGF induction in
inner ears by local EP2 or EP4 agonist application. We
then examined what type cochlear cells were responsible
for VEGF increase in the cochlea in response to local
application of EP2 or EP4 agonists. We thus performed
immunostaining for VEGF in cochlear specimens treated
with EP2 or EP4 agonist and in untreated cochlear speci-
mens. The untreated cochlear specimens showed little or
no staining for VEGF in the spiral ganglion neurons (Fig-
ure 4A), supporting cells, hair cells, spiral ligament, and
stria vascularis (data not shown). In the control speci-
mens treated with saline or DMSO, VEGF immunoreac-
tivity was weakly detectable in some of the spiral ganglion
neurons (Figure 4B, D). By contrast, intense immunore-
activity for VEGF was observed in the spiral ganglionHori et al. BMC Neuroscience 2010, 11:35
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neurons of the specimens treated with EP2 and EP4 ago-
nists (Figure 4C, E). The other EP2-positive and EP4-pos-
itive regions of the cochlea, including the supporting
cells, hair cells, spiral ligament, and stria vascularis,
showed little or no immunoreactivity for VEGF under all
of the experimental conditions, and no changes in VEGF
immunoreactivity were observed. These findings indicate
that the spiral ganglion neurons are responsible for the
increase in VEGF expression in the cochlea that results
from the local application of an EP2 or EP4 agonist.
VEGFR expression in cochleae
To examine the target cells of VEGF in the cochlea, we
performed immunostaining for VEGFRs, Flt-1 and Flk-1,
using non-treated cochlear specimens. Flt-1 expression
was detected in the supporting cells, hair cells, spiral gan-
glion neurons, and spiral ligament fibrocytes (Figure 5A-
C). Flk-1 expression was identified in the supporting cells,
hair cells, spiral ganglion neurons, spiral ligament fibro-
cytes, and stria vascularis marginal cells (Figure 5D-F).
These findings suggest that VEGF generated in the spiral
ganglion neurons in response to an EP2 or EP4 agonist
acts on cells expressing Flt-1 and/or Flk-1 in the cochlea
in a paracrine or autocrine fashion.
Figure 1 Immunoreactivity for EP2 in the cochlea. EP2 expression (red) was detected n the cochlear sensory epithelium (A; I, inner hair cell; O, outer 
hair cell; D, Deiter's cell; C, Claudius' cell), spiral ganglion neurons (B; SG), spiral ligament (C; ligament) and stria vascularis (C; SV). Nuclei were labeled 
with DAPI. The specimens were viewed with 63× oil objective. Scale bar = 200 μm.Hori et al. BMC Neuroscience 2010, 11:35
http://www.biomedcentral.com/1471-2202/11/35
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Discussion
Recently, the prostaglandin E receptor subtypes EP1, EP2,
EP3 and EP4 were cloned, and their specific agonists were
purified [7]. EP2 and EP4 are coupled to G-protein stimu-
lation and mediate increases in cAMP, while the activa-
tion of EP3 leads to a decrease of cAMP levels. We thus
hypothesized that selective agonists for EP2 and EP4
might be more effective than PGE1 for the treatment of
SNHL. In a previous study, we demonstrated the expres-
sion of EP4 in the cochlea, and the attenuation of noise-
induced damage as a result of local EP4 agonist adminis-
tration [9]. However, the mechanisms underlying the pro-
tective effect of EP4 against on cochlear damage have not
previously been investigated. In the present study, we
highlighted VEGF induction via EP2 or EP4 activation.
The present study therefore examined the effects of EP2
and EP4 agonists on the modulation of inner ear VEGF
levels.
We initially confirmed that EP2 expression occurred in
the cochlea and showed a similar pattern to EP4 expres-
sion [9]. ELISA and real-time qRT-PCR analyses demon-
strated an increase of VEGF protein and mRNA levels in
the inner ear after local EP2 or EP4 agonist application,
indicating that the stimulation of EP2 and/or EP4 acti-
vates VEGF production in the inner ear. Immunostaining
for VEGF showed that the strongest response to EP2 or
EP4 stimulation occurred in the spiral ganglion neurons,
suggesting that they are responsible for increasing the
VEGF levels in the inner ear. In addition, expression of
the VEGFRs Flt-1 and Flk-1 was identified in the sensory
epithelial cells, spiral ganglion neurons, spiral ligament
fibrocytes, and stria vascularis marginal cells, which was
consistent with previous findings [21]. These results indi-
cate that EP2 and EP4 are involved in the mechanisms
underlying the autocrine and paracrine functions of
VEGF in the inner ear. For mechanisms of VEGF induc-
tion via EP2 or EP4 activation, recent studies have indi-
cated involvement of cAMP- and PKA-dependent
mechanisms via SP-1 transcription factor binding sites on
the VEGF promoter [12,24,25]. However, further studies
are needed to determine signaling cascades for VEGF
induction via EP2 and EP4 in the inner ear.
VEGF was initially identified as a mitogen for endothe-
lial cells, which promotes angiogenesis and vascular per-
meability. Numerous studies have demonstrated that
VEGF plays crucial roles in the development and protec-
tion of neuronal cells [17,26]. VEGF and its receptors are
also present in the cochlea, and have been shown to play
significant roles in the maintenance of cochlear homeo-
stasis [20,21,27-30]. The present findings provide new
insights into the mechanisms underlying the regulation of
VEGF expression in the cochlea, which is mediated by
Figure 2 VEGF protein levels in the inner ear measured by ELISA. (A) VEGF protein levels in samples treated with 0.01 or 0.1 mg/ml EP2 agonist 
were significantly higher than those in samples treated with physiological saline (**, p < 0.01, and ***, p < 0.001, ANOVA with Scheffe's method). (B) 
VEGF protein levels in samples treated with 0.01 or 0.1 mg/ml EP4 agonist were significantly higher than those in samples treated with 0.01 or 0.1% 
DMSO, respectively (*, p < 0.05, **, p < 0.01, Student's t-test).Hori et al. BMC Neuroscience 2010, 11:35
http://www.biomedcentral.com/1471-2202/11/35
Page 5 of 9
EP2 and EP4. Past work has demonstrated that hypoxia-
inducible factor-1 induces VEGF upregulation in the
cochlea, which is involved in the cochlear pericyte
responses to noise trauma [30]. In the central nervous
system, VEGF synthesized by neurons was reported to
promote survival and angiogenesis, as well as autocrine
and paracrine neuronal survival [31]. The present results
demonstrated spiral ganglion neuron responses to EP2
and EP4 stimulation, and the expression of both Flt-1 and
Flk-1 in various cochlear components including the sen-
sory epithelium, spiral ganglion, and stria vascularis. Flk-
1 appears to mediate almost all of the known cellular
responses to VEGF [32], suggesting that Flk-1 also plays
an essential role in VEGF function in the cochlea. How-
ever, an actual answer for this awaits further investiga-
tions. Consequently, present findings indicate that VEGF
has autocrine and paracrine effects on neuronal and
endothelial cells in the cochlea as well as in the central
nervous system, and that EP2 and EP4 are involved in
autocrine and paracrine functions of VEGF in the
cochlea.
Hypoxic preconditioning is known to have protective
effects on neurons [33,34]. Recently, VEGF was reported
to be involved in the protective effect of neuronal precon-
Figure 3 Relative VEGF expression levels in inner ear according to real-time qRT-PCR. (A) Samples treated with EP2 agonist at 0.01 or 0.1 mg/
ml expressed higher levels of VEGF mRNAs than those treated with physiological saline. (B) Samples treated with EP4 agonist at 0.01 or 0.1 mg/ml 
expressed higher levels of VEGF mRNAs than those treated with 0.01 or 0.1% DMSO, respectively (*, p < 0.05, **, p < 0.01, and ***, p < 0.001, Student's 
t-test).
Figure 4 Immunoreactivity for VEGF in the spiral ganglion cells. Little or no staining was detected in the spiral ganglion cells of the untreated 
samples (A; Normal). VEGF expression (green) was weakly detected in a few spiral ganglion neurons in samples treated with physiological saline (B; 
Saline) and those treated with 0.1% DMSO (D; DMSO). VEGF expression was strongly detected in a large number of the spiral ganglion neurons treated 
with EP2 agonist (C; EP2 agonist) or EP4 agonist (E; EP4 agonist). Nuclei were labeled with DAPI. The specimens were viewed with 63× oil objective. 
Scale bar = 200 μm.Hori et al. BMC Neuroscience 2010, 11:35
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ditioning against ischemic injury [35]. Protection against
noise exposure by cochlear preconditioning has also been
documented [36]. VEGF upregulation in the cochlea is
induced not only by intense noise exposure [20,30] but
also by moderate noise exposure [21]. These findings sug-
gest that VEGF is also involved in the mechanisms under-
lying protection against noise exposure by cochlear
preconditioning. Our previous study demonstrated that
pretreatment with an EP4 agonist led to almost complete
protection of the cochleae against noise trauma [9]. In
addition, our present findings demonstrate the involve-
ment of EP2 and EP4 in the regulation of VEGF synthesis
in the inner ear. EP2-mediated and EP4-mediated VEGF
synthesis in the cochlea could therefore be associated
with protection against noise by cochlear precondition-
ing. However, distinct roles of VEGF in cochlear protec-
tion by local application of EP2 or EP4 agonists have not
been elucidated. Further studies are required to deter-
mine whether VEGF antagonists suppress protective
effects of EP2 or EP4 agonists for cochleae.
Conclusions
The present study demonstrated that local EP2 and EP4
agonist treatment induces VEGF synthesis in the inner
ear, especially in the spiral ganglion neurons. The expres-
sion of VEGFRs was detected in the cochlear sensory epi-
thelium, spiral ganglion, spiral ligament, and stria
vascularis. These findings indicate the involvement of
EP2 and EP4 in the autocrine and paracrine functions of
VEGF in the cochlea.
Methods
Animals
Male C57BL/6 mice at 8 weeks of age were purchased
from Japan SLC, Inc. (Hamamatsu, Japan). The Animal
Research Committee of the Graduate School of Medicine,
Kyoto University, Japan, approved all of the experimental
protocols. Animal care was supervised by the Institute of
Laboratory Animals of the Graduate School of Medicine,
Kyoto University. All of the experimental procedures
were performed in accordance with the National Insti-
tutes of Health (NIH) Guide for the Care and Use of Lab-
oratory Animals.
EP2 expression in cochleae
The expression of EP2 in the cochlea was immunohis-
tochemically examined using normal cochlear specimens
(n = 3). Under general anesthesia with midazolam (10
mg/kg; Astellas, Tokyo, Japan) and xylazine (10 mg/kg;
Bayer, Tokyo, Japan), the animals were transcardially per-
fused with 0.01 M phosphate-buffered saline (PBS; pH
7.4) followed by 4% paraformaldehyde (PFA) in PBS. The
temporal bones were immediately dissected out and
immersed in the same fixative for 2 h at 4°C. After decal-
cification with 0.1 M ethylenediamine tetra-acetic acid
(EDTA) for 7 days at 4°C, 10-μm-thick cryostat sections
were prepared. Two midmodiolus sections from each
cochlea were subjected to immunostaining for EP2. Anti-
EP2 polyclonal antibody (dilution, 1:250; Cayman Chemi-
cal, Ann Arbor, MI, USA) was used as the primary anti-
body, and Alexa 568-conjugated goat anti-rabbit
immunoglobulin G (IgG; dilution, 1:500; Invitrogen,
Figure 5 Immunoreactivity for Flt-1 and Flk-1 in the cochlea. (A-C) 
Flt-1 expression (green) was detected n the cochlear sensory epitheli-
um (A; I, inner hair cell; O, outer hair cell; D, Deiter's cell; C, Claudius' 
cell), spiral ganglion neurons (B; SG) and spiral ligament (C; ligament). 
(D-F) Flk-1 expression was found in the cochlear sensory epithelium 
(D), spiral ganglion neurons (E), spiral ligament (F) and stria vascularis 
(F; SV). Nuclei were labeled with DAPI. The specimens were viewed 
with 63× oil objective. Scale bar = 200 μm.Hori et al. BMC Neuroscience 2010, 11:35
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Carlsbad, CA, USA) was used as the secondary antibody.
After immunostaining for EP2, the nuclei were counter-
stained with 4,6-diamidino,2-phenylindole dihydrochlo-
ride (DAPI; 1 μg/ml in PBS; Molecular Probes, Eugene,
OR, USA). Heart specimens obtained from the mice were
used as positive controls for EP2. Nonspecific labeling
was tested by blocking protein-antibody complex forma-
tion using EP2-blocking peptide (Cayman Chemical).
The specimens were viewed with a Leica TCS-SPE confo-
cal microscope (Leica Microsystems, Wetzlar, Germany).
Local application of EP2 or EP4 agonist to inner ears
The EP2 agonist ONO-AE1-259-01 and the EP4 agonist
ONO-AE1-329 (both from Ono Pharmaceutical Co., Ltd.,
Osaka, Japan) were used in this study. The EP2 agonist
was dissolved in physiological saline to give a final con-
centration of 0.01, 0.1, or 1 mg/ml. The EP4 agonist was
dissolved in DMSO and diluted with physiological saline
to give a final concentration of 0.01, 0.1, or 1 mg/ml con-
taining 0.01, 0.1, or 1% DMSO, respectively. Controls for
EP2 agonist application were treated with saline, and con-
trols for EP4 agonist application were treated with 0.01,
0.1, or 1% DMSO. Drug application was performed under
general anesthesia with midazolam and xylazine as previ-
ously reported [37-39]. A retroauricular incision was
made in the left ear, and the posterior semicircular canal
(PSCC) was exposed. A small hole was made in the bony
wall of the PSCC. A fused silica glass needle (EiCOM,
Kyoto, Japan) was then inserted into the perilymphatic
space of the PSCC, and the appropriate material was
injected at a rate of 0.5 μl/min for 4 min (total = 2 μl)
using a micro syringe pump (EiCOM). At 24 h after the
injection into the PSCC, the animals were transcardially
perfused with PBS under general anesthesia with midazo-
lam and xylazine, and the inner ears were immediately
dissected out. The inner ear samples were subjected to
ELISA or real-time qRT-PCR analysis.
Quantitative assessments of VEGF
ELISA and real-time qRT-PCR analyses were employed
to assess the levels of VEGF proteins and mRNAs in the
inner ears treated with 0.01, 0.1, or 1 mg/ml EP2 agonist,
physiological saline, 0.01, 0.1, or 1 mg/ml EP4 agonist, or
0.01, 0.1, or 1% DMSO (n = 5 for each condition). ELISA
analyses for VEGF proteins were performed using a
mouse VEGF assay kit (Immuno-Biological Laboratories
Co., Ltd., Takasaki, Japan) according to the manufac-
turer's protocol. All reactions were performed in tripli-
cate.
For the real-time qRT-PCR analyses of VEGF mRNAs,
the inner ear samples were homogenized with Trizol
(Invitrogen), and total RNA was extracted using an
RNeasy mini kit (Qiagen Ltd., Valencia, CA, USA). To
eliminate genomic DNA contamination, the total RNA
was treated with DNaseI (Ambion, Austin, TX, USA).
The quantity and quality were evaluated using the A260/
280 ratio and the appearance of the 18S and 28S ribo-
somal RNA bands upon electrophoresis. Complementary
DNA (cDNA) was synthesized by reverse transcription
using TaqMan RT reagents (Applied Biosystems Inc.,
Foster City, CA, USA). The reactions were performed
using a GeneAmp PCR system 9700 (Applied Biosystems
Inc.) under the following conditions: 25°C for 10 min,
48°C for 30 min, 95°C for 5 min, and 4°C for 5 min. The
primers used in the real-time qRT-PCR for VEGF and for
the housekeeping gene glyceraldehydes 3-phosphate
dehydrogenase (GAPDH) were as follows: 5'-ACTTGT-
GTTGGGAGGAGGA-3' (sense) and 5'-AAAGGACT-
TCGGCCTCTCT-3' (antisense) for VEGF (97 base pairs
[bp]); and 5'-TGTGTCCGTCGTGGATCTGA-3' (sense)
and 5'-CCTGCTTCACCACCTTCTTGAT-3' (anti-
sense) for GAPDH (77 bp). The real-time qRT-PCR was
pe rf ormed a t  a  fi nal  vol um e  of  20 μ l a c c or di ng t o t he
manufacturer's protocols. The reaction mix comprised
template cDNA, 10 μl POWER SYBR Green Master Mix
(Applied Biosystems Inc.), a 0.5-μM final concentration
of each primer, and ribonuclease-free water. The amplifi-
cation conditions were as follows: 50°C for 2 min, 95°C
for 10 min, 40 cycles of denaturation at 95°C for 15 s, and
annealing at 60°C for 1 min. Fluorescence was detected
with the ABI Prism 7000 sequence detection system
(Applied Biosystems Inc.) and the associated software.
Negative controls without template were included, and all
reactions were performed in triplicate. The VEGF expres-
sion values were normalized to the housekeeping gene by
dividing the mean of the VEGF triplicate value by the
mean of the GAPDH triplicate value.
VEGF expression in cochleae
Immunohistochemistry was performed to examine the
localization of VEGF in cochlear specimens treated with
0.1 mg/ml EP2 agonist, physiological saline, 0.1 mg/ml
EP4 agonist, or 0.1% DMSO (n = 4 in each condition),
and in non-treated cochleae (n = 3). Two mid modiolus
sections from each cochlea were subjected to immunos-
taining for VEGF. Anti-mouse VEGF antibody (dilution, 5
μg/ml; R&D systems Inc., Minneapolis, MN, USA) was
used as the primary antibody, and Alexa 488-conjugated
donkey anti-goat IgG (dilution, 1:500; Invitrogen) was
used as the secondary antibody. Kidney specimens
obtained from the mice were used as positive controls.
Nonspecific labeling was tested by omitting the primary
antibody from the staining procedures.
VEGFR expression in cochleae
The expression of the VEGFRs Flt-1 and Flk-1 in normal
cochleae (n = 4) was examined by immunohistochemis-
try. Anti-mouse Flt-1 antibody (dilution, 25 μg/ml; R&DHori et al. BMC Neuroscience 2010, 11:35
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Systems Inc.) and anti-mouse Flk-1 antibody (dilution, 15
μg/ml; R&D systems Inc.) were used as the primary anti-
bodies, and Alexa 488-conjugated goat anti-rat IgG (dilu-
tion, 1:500; Invitrogen) and Alexa 488-conjugated donkey
anti-goat IgG (dilution, 1:500; Invitrogen) were used as
the secondary antibodies for Flt-1 and for Flk-1, respec-
tively. The positive and negative controls were the same
as those used in the VEGF immunostaining.
Statistical analysis
The differences in the levels of VEGF proteins among the
samples treated with EP2 were examined using the one-
factor analysis of variance with Scheffe's method. The dif-
ferences in the levels of VEGF proteins between the sam-
ples treated with EP4 agonist and the control samples and
those in the levels of and VEGF  mRNAs between
between the samples treated with EP2 or EP4 agonist and
the control samples were examined using the unpaired t-
test. A p value < 0.05 was considered statistically signifi-
cant. All data are represented as the mean ± standard
error.
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